Journal article Open Access

Systematic evaluation of the effects of metformin on the mTOR signalling pathway in the treatment of spinal cord injury

Yasin Emre Kaya

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="" xmlns="" xsi:schemaLocation="">
  <identifier identifierType="DOI">10.5281/zenodo.2550818</identifier>
      <creatorName>Yasin Emre Kaya</creatorName>
      <affiliation>Assist. Prof. M.D.; Abant Izzet Baysal University School of Medicine, Department of Orthopaedic and Traumatology, 14030, Bolu, Turkey</affiliation>
    <title>Systematic evaluation of the effects of metformin on the mTOR signalling pathway in the treatment of spinal cord injury</title>
    <subject>Metformin; mTOR  ignalling pathway, rapamycin; spinal cord injury, sirolimus</subject>
    <date dateType="Issued">2019-01-27</date>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
    <alternateIdentifier alternateIdentifierType="url"></alternateIdentifier>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.2550817</relatedIdentifier>
    <rights rightsURI="">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
    <description descriptionType="Abstract">&lt;p&gt;&lt;strong&gt;Metformin is one of the safest drugs used to control blood sugar in diabetes. This drug is being investigated by orthopedists as well as by neurosurgeons as it may increase the locomotor recovery after spinal cord injury (SCI). In the present study, the aim was to evaluate a promising pharmacological agent, metformin, which is known to be used in SCI treatment by acting over the mammalian target of rapamycin (mTOR) and some other signaling pathway. Relevant clinical trials were included in the study following electronic database scan. &amp;nbsp;Preclinical and cellular studies have demonstrated that metformin may have antitumoral properties, regulate inflammation, and therefore play a role in the tumor microenvironment, or that it has a therapeutic effect in SCI by acting over mTOR pathway. However, Level of I clinical trials should be performed to determine the effectiveness of metformin in SCI, a serious pathology.&lt;/strong&gt;&lt;/p&gt;</description>
All versions This version
Views 99
Downloads 11
Data volume 161.1 kB161.1 kB
Unique views 99
Unique downloads 11


Cite as